33 related articles for article (PubMed ID: 21395964)
1. Determinants of highly active antiretroviral therapy duration in HIV-1-infected children and adolescents in Madrid, Spain, from 1996 to 2012.
Palladino C; Briz V; Bellón JM; Climent FJ; de Ory SJ; Mellado MJ; Navarro ML; Ramos JT; Taveira N; de José MI; Muñoz-Fernández MÁ;
PLoS One; 2014; 9(5):e96307. PubMed ID: 24788034
[TBL] [Abstract][Full Text] [Related]
2. Canadian consensus guidelines for the optimal use of etravirine in the treatment of HIV-infected adults.
Harris M; Angel JB; Baril JG; Rachlis A; Trottier B
Can J Infect Dis Med Microbiol; 2009; 20(2):e24-34. PubMed ID: 20514155
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand.
European Pregnancy And Paediatric Infections Cohort Collaboration Eppicc ; Lyons A; Thompson L; Chappell E; Ene L; Galli L; Goetghebuer T; Jourdain G; Noguera-Julian A; Kahlert CR; Königs C; Kosalaraksa P; Lumbiganon P; Marczyńska M; Marques L; Navarro M; Naver L; Okhonskaia L; Prata F; Puthanakit T; Ramos JT; Samarina A; Thorne C; Voronin E; Turkova A; Giaquinto C; Judd A; Collins IJ
Antivir Ther; 2022 Jun; 27(3):13596535221092182. PubMed ID: 36029009
[TBL] [Abstract][Full Text] [Related]
4. Raltegravir use and outcomes among children and adolescents living with HIV in the IeDEA global consortium.
Patten G; Puthanakit T; McGowan CC; Wools-Kaloustian K; Hazra R; Pinto JA; Machado D; Succi R; Sohn AH; Rabie H; Musick B; Davies MA;
J Int AIDS Soc; 2020 Jul; 23(7):e25580. PubMed ID: 32722897
[TBL] [Abstract][Full Text] [Related]
5. The Lipodystrophy Syndrome in HIV-Infected Children under Antiretroviral Therapy: A First Report from the Central Africa.
Tshamala HK; Aketi L; Tshibassu PM; Ekila MB; Mafuta EM; Kayembe PK; Aloni MN; Shiku JD
Int J Pediatr; 2019; 2019():7013758. PubMed ID: 30941184
[TBL] [Abstract][Full Text] [Related]
6. Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.
Bamford A; Turkova A; Lyall H; Foster C; Klein N; Bastiaans D; Burger D; Bernadi S; Butler K; Chiappini E; Clayden P; Della Negra M; Giacomet V; Giaquinto C; Gibb D; Galli L; Hainaut M; Koros M; Marques L; Nastouli E; Niehues T; Noguera-Julian A; Rojo P; Rudin C; Scherpbier HJ; Tudor-Williams G; Welch SB;
HIV Med; 2018 Jan; 19(1):e1-e42. PubMed ID: 25649230
[TBL] [Abstract][Full Text] [Related]
7. The emergence of drug resistant HIV variants and novel anti-retroviral therapy.
Paydary K; Khaghani P; Emamzadeh-Fard S; Alinaghi SA; Baesi K
Asian Pac J Trop Biomed; 2013 Jul; 3(7):515-22. PubMed ID: 23835806
[TBL] [Abstract][Full Text] [Related]
8. The role of etravirine in the management of treatment-experienced pediatric patients with HIV.
Osterholzer D
HIV AIDS (Auckl); 2013; 5():67-73. PubMed ID: 23610529
[TBL] [Abstract][Full Text] [Related]
9. A new tool for the paediatric HIV research: general data from the Cohort of the Spanish Paediatric HIV Network (CoRISpe).
de Jose MI; Jiménez de Ory S; Espiau M; Fortuny C; Navarro ML; Soler-Palacín P; Muñoz-Fernandez MA;
BMC Infect Dis; 2013 Jan; 13():2. PubMed ID: 23282073
[TBL] [Abstract][Full Text] [Related]
10. When to start, what to start and other treatment controversies in pediatric HIV infection.
Turkova A; Webb RH; Lyall H
Paediatr Drugs; 2012 Dec; 14(6):361-76. PubMed ID: 23013459
[TBL] [Abstract][Full Text] [Related]
11. Etravirine: a guide to its use in treatment-experienced pediatric patients with HIV-1 infection in the US.
Lyseng-Williamson KA
Paediatr Drugs; 2012 Oct; 14(5):345-50. PubMed ID: 22897163
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Puthanakit T; Jourdain G; Hongsiriwon S; Suntarattiwong P; Chokephaibulkit K; Sirisanthana V; Kosalaraksa P; Petdachai W; Hansudewechakul R; Siangphoe U; Suwanlerk T; Ananworanich J;
HIV Med; 2010 Oct; 11(9):565-72. PubMed ID: 20345882
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
Boffito M; Winston A; Jackson A; Fletcher C; Pozniak A; Nelson M; Moyle G; Tolowinska I; Hoetelmans R; Miralles D; Gazzard B
AIDS; 2007 Jul; 21(11):1449-55. PubMed ID: 17589191
[TBL] [Abstract][Full Text] [Related]
14. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
15. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
Schiller DS; Youssef-Bessler M
Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
[TBL] [Abstract][Full Text] [Related]
16. Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients.
Briz V; Palladino C; Navarro M; Jiménez de Ory S; González-Tomé M; León J; Núñez-Cuadros E; de José M; Ramos J; Muñoz-Fernández M
HIV Med; 2011 Aug; 12(7):442-6. PubMed ID: 21395964
[TBL] [Abstract][Full Text] [Related]
17. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.
Briz V; León-Leal JA; Palladino C; Moreno-Perez D; de Ory SJ; De José MI; González-Tomé MI; Martín CG; Pocheville I; Ramos JT; Leal M; Muñoz-Fernández MÁ
Pediatr Infect Dis J; 2012 Mar; 31(3):273-7. PubMed ID: 22330165
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
